Mette Bjerre

Pregnancy-associated plasma proteins and Stanniocalcin-2 - Novel players controlling IGF-I physiology

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

DOI

  • Jan Frystyk, Endocrine Research Unit, Department of Endocrinology, Odense University Hospital, Odense, Denmark.
  • ,
  • Enrique Teran, Escuela Politecn Nacl Ecuador, Escuela Politecnica Nacional Ecuador, Dept Biol
  • ,
  • Mette Faurholdt Gude
  • Mette Bjerre
  • Rikke Hjortebjerg, Endocrine Research Unit, Department of Endocrinology, Odense University Hospital, Odense, Denmark.

IGF-I was originally discovered as a GH-dependent growth factor stimulating longitudinal growth. Currently, however, it has become evident that the biological activities of IGF-I extend well beyond those of a simple growth factor and impact such processes as insulin sensitivity, aging, cancer and cardiovascular disease. The vast majority of IGF-I is tightly bound to IGF-binding proteins (IGFBPs), which renders IGF-I unable to stimulate the IGF-I receptor (IGF-IR) in vivo. This binding means that liberation of IGF-I from the IGFBPs is an important step controlling IGF-I action. In this context, IGFBP-cleaving enzymes appear to play a key role. Enzymatic cleavage of the IGFBPs markedly lowers their ligand affinity, and as a consequence, IGF-I becomes liberated and hence available for stimulation of the IGF-IR. Two of the best-characterized IGFBP-cleaving enzymes are pregnancy-associated plasma protein-A (PAPP-A) and its paralog PAPP-A2. The two enzymes (often referred to as pappalysins) regulate the liberation of IGF-I in a highly controlled manner. PAPP-A is believed to act predominantly in tissues, serving to liberate IGF-I at the cell surface in close proximity to the IGF-IR. In keeping with this notion, mice lacking PAPP-A exhibit reduced body size, despite having normal circulating IGF-I concentrations. In contrast, human findings indicate that altered PAPP-A2 activity changes circulating IGF-I concentrations, although PAPP-A2 is also present in high concentrations in tissues. Thus, PAPP-A2 appears to impact circulating, as well as tissue, IGF-I activity. The enzymatic activity of PAPP-A and PAPP-A2 was recently discovered to be regulated by the protein Stanniocalcin-2 (STC2). By binding to the enzymatic sites of PAPP-A and PAPP-A2, STC2 inhibits their activity. To date, the majority of findings demonstrating the ability of pappalysins and STC2 to regulate IGF-I action are from preclinical studies. However, clinical studies are now beginning to emerge. In this review, we will summarize our data on STC2, PAPP-A and PAPP-A2 in humans. These results indicate that pappalysins and STC2 constitute an important IGF-I activity-regulating system that warrants further investigation.

OriginalsprogEngelsk
Artikelnummer101330
TidsskriftGrowth Hormone & I G F Research
Vol/bind53-54
NummerAugust-October
Antal sider8
ISSN1096-6374
DOI
StatusUdgivet - 2020

Bibliografisk note

Copyright © 2020 Elsevier Ltd. All rights reserved.

Se relationer på Aarhus Universitet Citationsformater

ID: 193337796